; and (ii) furnishes an assistive telehealth consultation to an eligible telehealth individual an amount equal to the amount that a physician or practitioner would have been paid for such telehealth service under paragraph (2). (C) Tests described For purposes of subparagraphs (A) and (B), a test described in this subparagraph is a medical device (as defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act) or is a test approved under an emergency use authorization under section 564 of such Act and is either— (i) a diagnostic laboratory test for the diagnosis of influenza or a similar respiratory condition that is required to obtain a final diagnosis of COVID–19 for an individual when such test is ordered by a physician or practitioner in conjunction with a COVID–19 diagnostic laboratory test for purposes of discounting a diagnosis of influenza or a related diagnosis for such individual; or (ii) a serology test for COVID–19. (D) Other matters relating to documentation and claims review The requirements of paragraphs (2) and (3) of section 410.32(d) of title 42, Code of Federal Regulations (as in effect on the date of the enactment of this paragraph), relating to documentation and claims review, respectively, shall apply to a test described in subparagraph (C) and an assistive telehealth consultation. (E) Demographic data To be eligible for reimbursement under this paragraph, each claim for reimbursement shall include, with respect to such an eligible telehealth individual, the following demographic data: (i) Age. (ii) Race and ethnicity. (iii) Gender. (iv) An affirmative or negative statement of the existence of any chronic condition. (v) Any other information the Secretary determines appropriate. (F) Assistive telehealth consultation In this paragraph, the term assistive telehealth consultation means a telehealth service (as defined in paragraph (4)(F)) that is— (i) an evaluation and management service